62 assets in Neuroblastoma

Therapeutic assets addressing Neuroblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Neuroblastoma	Robbie Majzner	P2	BB (67)
Irinotecan Neuroblastoma	Milton S. Hershey Medical Center	P2	BB (65)
Nogitecan Neuroblastoma	Novartis Pharmaceuticals	P2	BB (65)
Nivolumab Neuroblastoma	Instituto do Cancer do Estado de São Paulo	P2	BB (64)
Olaparib Neuroblastoma	Fundación de investigación HM	P2	BB (64)
Ipilimumab Neuroblastoma	Children's National Research Institute	P2	B (63)
(+)-Vincristine Neuroblastoma	Theodore Laetsch	P2	B (63)
Fludarabine Neuroblastoma	Robbie Majzner	P2	B (62)
FDOPA Neuroblastoma	University of Alberta	P3	B (59)
Furosemide Neuroblastoma	University of Alberta	P3	B (57)
Palbociclib Neuroblastoma	Pfizer	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Neuroblastoma	National Cancer Institute (NCI)	P2	B (57)
Selumetinib Neuroblastoma	National Cancer Institute (NCI)	P2	B (57)
Tazemetostat Neuroblastoma	National Cancer Institute (NCI)	P2	B (57)
Alectinib Neuroblastoma	Cancer Research UK	P2/3	CCC (55)
Vemurafenib Neuroblastoma	National Cancer Institute (NCI)	P2	CCC (55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Neuroblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Anti-Gd2-Car Engineered T Cells Neuroblastoma	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (53)
Cabozantinib Neuroblastoma	Nationwide Children's Hospital	P2	CCC (53)
Ensartinib Neuroblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Ivosidenib Neuroblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Neuroblastoma	National Cancer Institute (NCI)	P2	CCC (53)
L-Methionine Neuroblastoma	St. Jude Children's Research Hospital	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Neuroblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Neuroblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Neuroblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Capmatinib Neuroblastoma	Cancer Research UK	P2/3	CCC (50)
Targeting Cd276 Car T Cells Neuroblastoma	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (50)
Zoledronate Neuroblastoma	University of Florida	P1/2	CCC (50)
Eb-Dtnb-Nk Neuroblastoma	Beijing Biotech	P1/2	CCC (48)
Hbi 0201-Eso Tcrt Neuroblastoma	Hadassah Medical Organization	P1/2	CCC (48)
Onivyde Neuroblastoma	St. Jude Children's Research Hospital	P1/2	CCC (48)
Oxodotreotide Neuroblastoma	Fundación de investigación HM	P1/2	CCC (48)
Peel-224 Neuroblastoma	Theodore Laetsch	P1/2	CCC (48)
Talazoparib Neuroblastoma	St. Jude Children's Research Hospital	P1/2	CCC (48)
Vorinostat Neuroblastoma	New York Medical College	P1	CC (47)
gd2-cart01 Neuroblastoma	Bambino Gesù Hospital and Research Institute	P1/2	CC (45)
Silmitasertib Neuroblastoma	Milton S. Hershey Medical Center	P1/2	CC (45)
Tegavivint Neuroblastoma	Children's Oncology Group	P1/2	CC (45)
Zilovertamab Vedotin Neuroblastoma	Merck Sharp & Dohme LLC	P1/2	CC (45)
Ribociclib Neuroblastoma	Novartis Pharmaceuticals	P1	CC (44)
c7r-gd2.cart cells Neuroblastoma	Baylor College of Medicine	P1	CC (43)
GD2-SADA Neuroblastoma	Y-mAbs Therapeutics	P1	CC (43)
<Sup>177</Sup>Lu-Dota Neuroblastoma	Y-mAbs Therapeutics	P1	CC (43)
Anti-Egfr Antibody-Drug Conjugate Mrg003 Neuroblastoma	Sun Yat-sen University	P1	CC (41)
Apg 115 Neuroblastoma	Ascentage Pharma Group Inc.	P1	CC (41)
Avutometinib Neuroblastoma	Memorial Sloan Kettering Cancer Center	P1	CC (41)
b7-h3cart Neuroblastoma	Stanford University	P1	CC (41)
b7-h3 car t cells Neuroblastoma	St. Jude Children's Research Hospital	P1	CC (41)
b7-h3.cd28z.cart Neuroblastoma	Robbie Majzner	P1	CC (41)

Showing 1 to 50 of 62 assets

PreviousPage 1 of 2Next